Craig Bijou
Stock Analyst at B of A Securities
(3.75)
# 636
Out of 5,182 analysts
70
Total ratings
58.97%
Success rate
51.65%
Average return
Main Sectors:
Stocks Rated by Craig Bijou
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRCT PROCEPT BioRobotics | Downgrades: Underperform | $38 → $20 | $24.09 | -16.98% | 6 | Feb 26, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Neutral | $82 → $92 | $70.48 | +30.53% | 3 | Jan 5, 2026 | |
| GMED Globus Medical | Upgrades: Buy | $65 → $91 | $93.70 | -2.88% | 5 | Nov 7, 2025 | |
| RXST RxSight | Maintains: Underperform | $18 → $9 | $7.29 | +23.46% | 2 | Jul 9, 2025 | |
| TFX Teleflex | Downgrades: Underperform | $235 → $140 | $135.07 | +3.65% | 5 | Mar 4, 2025 | |
| BLCO Bausch + Lomb | Maintains: Underperform | $18 → $17 | $15.88 | +7.05% | 3 | Feb 20, 2025 | |
| IART Integra LifeSciences Holdings | Maintains: Underperform | $26 → $18 | $10.69 | +68.38% | 13 | Oct 7, 2024 | |
| ITGR Integer Holdings | Maintains: Buy | $135 → $145 | $85.35 | +69.89% | 3 | Oct 1, 2024 | |
| MMSI Merit Medical Systems | Maintains: Neutral | $92 → $103 | $67.43 | +52.75% | 3 | Sep 16, 2024 | |
| HAE Haemonetics | Initiates: Neutral | $85 | $60.48 | +40.54% | 1 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $95 | $64.34 | +47.65% | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $36 | $13.15 | +173.76% | 2 | Jan 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 → $45 | $8.07 | +457.62% | 3 | May 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $120 | $11.37 | +955.41% | 2 | Mar 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $30 | $6.07 | +394.23% | 5 | Mar 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8.5 → $6.5 | $16.50 | -60.61% | 2 | Mar 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $48 → $42 | $12.32 | +240.91% | 3 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $207 → $230 | $470.99 | -51.17% | 1 | Jan 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $190 → $230 | $329.01 | -30.09% | 4 | Jul 26, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.94 | - | 3 | Dec 4, 2017 |
PROCEPT BioRobotics
Feb 26, 2026
Downgrades: Underperform
Price Target: $38 → $20
Current: $24.09
Upside: -16.98%
GE HealthCare Technologies
Jan 5, 2026
Maintains: Neutral
Price Target: $82 → $92
Current: $70.48
Upside: +30.53%
Globus Medical
Nov 7, 2025
Upgrades: Buy
Price Target: $65 → $91
Current: $93.70
Upside: -2.88%
RxSight
Jul 9, 2025
Maintains: Underperform
Price Target: $18 → $9
Current: $7.29
Upside: +23.46%
Teleflex
Mar 4, 2025
Downgrades: Underperform
Price Target: $235 → $140
Current: $135.07
Upside: +3.65%
Bausch + Lomb
Feb 20, 2025
Maintains: Underperform
Price Target: $18 → $17
Current: $15.88
Upside: +7.05%
Integra LifeSciences Holdings
Oct 7, 2024
Maintains: Underperform
Price Target: $26 → $18
Current: $10.69
Upside: +68.38%
Integer Holdings
Oct 1, 2024
Maintains: Buy
Price Target: $135 → $145
Current: $85.35
Upside: +69.89%
Merit Medical Systems
Sep 16, 2024
Maintains: Neutral
Price Target: $92 → $103
Current: $67.43
Upside: +52.75%
Haemonetics
Sep 11, 2024
Initiates: Neutral
Price Target: $85
Current: $60.48
Upside: +40.54%
Oct 30, 2023
Initiates: Buy
Price Target: $95
Current: $64.34
Upside: +47.65%
Jan 18, 2022
Maintains: Buy
Price Target: $43 → $36
Current: $13.15
Upside: +173.76%
May 13, 2020
Reiterates: Overweight
Price Target: $23 → $45
Current: $8.07
Upside: +457.62%
Mar 25, 2020
Maintains: Overweight
Price Target: $15 → $120
Current: $11.37
Upside: +955.41%
Mar 24, 2020
Maintains: Neutral
Price Target: $60 → $30
Current: $6.07
Upside: +394.23%
Mar 24, 2020
Reiterates: Overweight
Price Target: $8.5 → $6.5
Current: $16.50
Upside: -60.61%
Feb 25, 2020
Maintains: Neutral
Price Target: $48 → $42
Current: $12.32
Upside: +240.91%
Jan 10, 2020
Reiterates: Overweight
Price Target: $207 → $230
Current: $470.99
Upside: -51.17%
Jul 26, 2019
Maintains: Neutral
Price Target: $190 → $230
Current: $329.01
Upside: -30.09%
Dec 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $9.94
Upside: -